Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma

Science China Life Sciences

Volumn 56, Issue 7, 2013, Pages 638-646

  Yang, Lei ^a   Rong, WeiQi ^a   Xiao, Ting ^a   Zhang, Ying ^a   Xu, Bin ^b   Liu, Yu ^a   Wang, LiMing ^a   Wu, Fan ^a   Qi, Jun ^a   Zhao, XiuYing ^c   Wang, HongXia ^b   Han, NaiJun ^a   Guo, SuPing ^a   Wu, JianXiong ^a   Gao, YanNing ^a   Cheng, ShuJun ^a  

^a CANCER HOSPITAL   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

biomarker; hepatocellular carcinoma (HCC); MMP1; OPN; PSG9; secretome

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; INTERSTITIAL COLLAGENASE; OSTEOPONTIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEOME; TRANSFORMING GROWTH FACTOR BETA;

AREA UNDER THE CURVE; ARTICLE; BIOLOGY; CHEMISTRY; CULTURE MEDIUM; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; VIROLOGY;

ALPHA-FETOPROTEINS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COMPUTATIONAL BIOLOGY; CULTURE MEDIA, CONDITIONED; CULTURE MEDIA, SERUM-FREE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; OSTEOPONTIN; PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEINS; PROTEOME; PROTEOMICS; ROC CURVE; TRANSFORMING GROWTH FACTOR BETA;

HEPATITIS B VIRUS;

EID: 84879936789     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4497-x     Document Type: Article

References (34)

1. Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61: 69-90.
2. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27: 6550-6557.
3. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg, 2006, 243: 229-235.
4. Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol, 2007, 14: 2337-2347.
5. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 2010, 59: 1687-1693.
6. States D J, Omenn G S, Blackwell T W, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol, 2006, 24: 333-338.
7. Meng R, Gormley M, Bhat V B, et al. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics, 2011, 75: 366-374.
8. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics, 2010, 73: 2291-2305.
9. Planque C, Kulasingam V, Smith C R, et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics, 2009, 8: 2746-2758.
10. Polisetty R V, Gupta M K, Nair S C, et al. Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J Proteomics, 2011, 74: 1918-1925.
11. Xiao T, Ying W, Li L, et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics, 2005, 4: 1480-1486.
12. Zhang Y, Xu B, Liu Y, et al. The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics, 2012, 12: 1883-1891.
13. Lechner J F, LaVeck M A. A serum-free method for culturing normal human bronchial epithelial cells at clonal density. J Tissue Cult Methods, 1985, 9: 43-48.
14. Shen Z, Li P, Ni R J, et al. Label-free quantitative proteomics analysis of etiolated maize seedling leaves during greening. Mol Cell Proteomics, 2009, 8: 2443-2460.
15. Sun H, Fang H, Chen T, et al. GOFFA: gene ontology for functional analysis-a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics, 2006, 7(Suppl 2): S23.
16. Wu S, Wan P, Li J, et al. Multi-modality of pI distribution in whole proteome. Proteomics, 2006, 6: 449-455.
17. Omenn G S, States D J, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics, 2005, 5: 3226-3245.
18. Anderson N L, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics, 2004, 3: 311-326.
19. Chinese Human Liver Proteome Profiling Consortium. First insight into the human liver proteome from PROTEOME(SKY)-LIVER(Hu) 1. 0, a publicly available database. J Proteome Res, 2010, 9: 79-94.
20. Lin L, Amin R, Gallicano G I, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene, 2009, 28: 961-972.
21. Pavlou M P, Diamandis E P. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics, 2010, 73: 1896-1906.
22. Sun S, Xu M Z, Poon R T, et al. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res, 2010, 9: 70-78.
23. Luk J M, Lam C T, Siu A F, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics, 2006, 6: 1049-1057.
24. Murata M, Matsuzaki K, Yoshida K, et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology, 2009, 49: 1203-1217.
25. Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 2007, 26: 6361-6371.
26. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55: 483-490.
27. Sun J, Xu H M, Zhou H J, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2010, 136: 1-7.
28. Salahshor S, Goncalves J, Chetty R, et al. Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer, 2005, 5: 66.
29. Lisboa F A, Warren J, Sulkowski G, et al. Pregnancy-specific glycoprotein 1 induces endothelial tubulogenesis through interaction with cell surface proteoglycans. J Biol Chem, 2011, 286: 7577-7586.
30. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010, 141: 52-67.
31. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology, 2005, 129: 2064-2075.
32. Liu D, Guo H, Li Y, et al. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS ONE, 2012, 7: e31251.
33. Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer, 2008, 8: 77.
34. Li M, Xiao T, Zhang Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer, 2010, 69: 341-347.